Conditions: Atrial Fibrillation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 6421
Healthy volunteers: no

Brief summary:
The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.

Detailed description:
An optional Long-term Open-label Extension Phase of treatment with apixaban will be provided for qualifying participants following the conclusion of the double-blind phase

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Apixaban intervention 2: Acetylsalicylic acid
Intervention descriptions: intervention 1: Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks intervention 2: Tablets, oral, 81-324 mg, once daily, up to 156 weeks

Protocol document: